Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetWages, Salaries and Other
Ratios

Sutro Biopharma (STRO) Receivables - Other (2017 - 2020)

Sutro Biopharma (STRO) has disclosed Receivables - Other for 4 consecutive years, with $6.4 million as the latest value for Q1 2020.

  • Quarterly Receivables - Other rose 439.06% to $6.4 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $6.4 million through Mar 2020, up 439.06% year-over-year, with the annual reading at $1.0 million for FY2019, 9.49% up from the prior year.
  • Receivables - Other hit $6.4 million in Q1 2020 for Sutro Biopharma, up from $1.0 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $6.4 million in Q1 2020 to a low of $784000.0 in Q4 2017.
  • Historically, Receivables - Other has averaged $1.9 million across 4 years, with a median of $1.1 million in 2019.
  • Biggest five-year swings in Receivables - Other: increased 9.49% in 2019 and later surged 439.06% in 2020.
  • Year by year, Receivables - Other stood at $784000.0 in 2017, then grew by 22.32% to $959000.0 in 2018, then rose by 9.49% to $1.0 million in 2019, then surged by 509.9% to $6.4 million in 2020.
  • Business Quant data shows Receivables - Other for STRO at $6.4 million in Q1 2020, $1.0 million in Q4 2019, and $2.1 million in Q3 2019.